Aspiro Pharma Limited - pharma in Markook, Telangana, India. FY 2026 financials & compliance.
CIN U24100TG2014PLC092771 Incorporated 05 February 2014 ROC Hyderabad HQ Markook, Telangana, India
Active Public Limited Company pharma
Revenue · FY 2025
₹418.29 Cr
▲ 147% YoY
Net profit · FY 2025
₹25.39 Cr
Net margin 6.1%
EBITDA · FY 2025
₹84.99 Cr
EBITDA margin 20.3%
Authorised capital
₹1,470.1 Cr
Registered with MCA
Paid-up capital
₹1,004.15 Cr
Issued & subscribed
Open charges
₹206.91 Cr
Satisfied ₹46.89 Cr
Company age
12 yrs
Est. 2014
Employees · EPFO
749
Provident fund records

About Aspiro Pharma Limited

Data last updated:

Aspiro Pharma Limited is a public limited company based in Markook, Telangana, India, a subsidiary of Hetero Labs Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 February 2014 and has been in existence for over 12 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24100TG2014PLC092771. Its GSTIN is 36AAMCA4474H1ZF (Telangana). The company holds 2 GST registrations, of which 1 is active.

The company has an authorised share capital of ₹1,470.1 Cr and a paid-up capital of ₹1,004.15 Cr. It is led by directors including Bandi Vamsikrishna and Reddy Narsimha.

Its last annual general meeting (AGM) was held on 24 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 321 Biotech Park, Markook, Telangana.

As per the financials filed for FY 2025, the company reported a revenue of ₹418.29 Cr, a growth of 147% compared to the previous year. For the same year it recorded a net profit of ₹25.39 Cr (net margin 6.1%) and EBITDA of ₹84.99 Cr (EBITDA margin 20.3%). Revenue has grown at a compounded annual rate (CAGR) of 67% over three years and 80% over five years.

The company has about 749 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Aspiro Pharma. As per MCA filings, the company has open charges of ₹206.91 Cr and satisfied charges of ₹46.89 Cr on record. Court records list 9 cases involving the company, including 2 filed by the company and 7 filed against it. The company has 8 deals on record (5 funding rounds, 3 secondary share transfers), with disclosed funding of ₹998.75 Cr; the latest was in October 2025. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 3 larger and 1 smaller; the largest is Milan Laboratories (India) Private Limited with revenue of ₹429.23 Cr. The company has 12 MSME Form 1 returns on record between 2016 and 2024, listing 198 overdue payments to 48 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aspiropharma.com.

Company details

CIN U24100TG2014PLC092771
Registration Number 092771
Incorporation Date 05 February 2014
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Parent Company Hetero Labs Limited
Compliance Status Active Compliant

CIN history

Aspiro Pharma has one previous CIN (Corporate Identification Number): U24100AP2014PLC092771. The current CIN is U24100TG2014PLC092771, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24100TG2014PLC092771Current
U24100AP2014PLC092771Previous

Contact details

Aspiro Pharma Limited's registered office is in Markook, Telangana. Its website is aspiropharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    Plot No. 23 Survey No.321 Biotech Park Phase – III Karkapatla Villa, Ge, Markook, Telangana, India – 502281
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Aspiro Pharma Limited, buy the company report.

Comprehensive company report
Aspiro Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Aspiro Pharma operates one associated brand: Aspiro Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Research, development, and manufacturing of pharmaceutical formulations in India.aspiropharma.com

Business activity

The main business activity of Aspiro Pharma is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Aspiro Pharma Limited, buy the company report.

Financials of Aspiro Pharma Limited

FY 2025 filings available

Aspiro Pharma Limited reported revenue of ₹418.29 Cr (up 147% YoY) for FY 2025.

Revenue · FY 2025
₹418.29 Cr ▲ 147%
Net profit · FY 2025
₹25.39 Cr margin 6.1%
EBITDA · FY 2025
₹84.99 Cr margin 20.3%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 147%
3 years · compounded
▲ 67%
5 years · compounded
▲ 80%
EBITDA CAGR growth
1 year
▲ 316%
5 years · compounded
▲ 33%

Revenue has grown at a compounded annual rate (CAGR) of 80% over five years, including 147% growth in the latest year. EBITDA rose 316% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹418.29 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹84.99 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹25.39 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin20.3%
Net Profit Margin6.1%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Aspiro Pharma Limited, buy the company report.

Board of directors of Aspiro Pharma Limited

Aspiro Pharma has 6 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Bandi VamsikrishnaDirector13 Feb 201412 Years 9 MonthsCurrent
Reddy NarsimhaDirector03 Aug 20242 Years 3 MonthsCurrent
Krishnaveni KuraDirector29 Jun 20179 Years 4 MonthsCurrent
Ramaseshappa Siva Prasad PanchangamDirector03 Aug 20233 Years 3 MonthsCurrent
Mahesh Ramappa Kamalamma HassanDirector07 Jun 20233 Years 5 MonthsCurrent
Bhaskarreddy PabbatireddyAdditional Director10 Oct 20251 Years 1 MonthsCurrent

Peer comparison

Aspiro Pharma Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Milan Laboratories (India) Private Limited₹429.23 Cr (FY 2024)42.0%Thane, Maharashtra, India
Recipharm Pharmaservices Private Limited₹421.11 Cr (FY 2025)-3.0%Mumbai, Maharashtra, India
Albert David Ltd₹420.01 Cr (FY 2024)18.0%Kolkata, West Bengal, India
Aspiro Pharma Limitedthis company₹418.29 Cr (FY 2025)₹25.39 Cr6.1%147.0%749Markook, Telangana, India
Themis Medicare Limited₹410.18 Cr (FY 2025)6.0%Vapi, Gujarat, India

To see the full peer comparison of Aspiro Pharma Limited, buy the company report.

Auditor

Aspiro Pharma Limited is audited by Suryanarayana Reddy and Co for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Suryanarayana Reddy and CoFY 2025005752S

Shareholding

The shareholding of Aspiro Pharma Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2025FY 2024FY 2023FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Aspiro Pharma Limited, buy the company report.

Charges & borrowings

Open charges
₹206.91 Cr
Satisfied charges
₹46.89 Cr
Breakdown by lending institutions
Others₹206.24 Cr
Hdfc Bank Limited₹0.67 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Sep 2024100989753Others₹100 CrOpen
10 May 2024100928366Others₹9 LakhOpen
03 Apr 2024100907989Others₹105 CrOpen
04 Nov 2023100824319Others₹13 LakhOpen
26 Oct 2023100809427Others₹10.24 LakhOpen

To see the full charge records of Aspiro Pharma Limited, buy the company report.

Total charge records: 16 View all charges

Deals & funding

Aspiro Pharma Limited has 8 deals on record (5 funding rounds, 3 secondary share transfers), with disclosed funding of ₹998.75 Cr; the latest was in October 2025.

Total deals
8
Funding rounds
5
Secondary share transfers
3
Disclosed funding
₹998.75 Cr

Deals on record (5 of 8)

WhenDealAmountParties
Oct 2025Funding round₹600 CrInvestors: Hetero Labs Limited
Oct 2024Secondary share transferUndisclosedBuyer: Hetero Labs Limited
Seller: an individual
Mar 2022Funding round₹150 CrInvestors: Hetero Labs Limited
May 2018Funding round₹26.36 CrInvestors: Hetero Labs Limited
Jun 2017Funding round₹82.91 CrInvestors: Hetero Labs Limited

To see the full deal history of Aspiro Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Aspiro Pharma Limited has 12 MSME Form 1 returns on record between 2016 and 2024, listing 198 overdue payments to 48 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 48)

SupplierAmount dueDue sinceReported on
Yuno Packaging Private Limited
Nicomac Taikisha Clean Rooms Private Limited
Sri Sri Sai Ram Print Pack
Citrus Packaging Solutions Private Limited
S.R.Automations

To see the full MSME payment records of Aspiro Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Aspiro Pharma has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Strivo Pharma Private LimitedU24302TG2016PTC109188

To see the full group structure of Aspiro Pharma Limited, buy the company report.

Employees & EPFO

Aspiro Pharma Limited has a workforce of 749 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
749
Active EPFO establishments
1
Employee growth
47.7%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27749
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17
FY 2014-15

To see the full employee and EPFO history of Aspiro Pharma Limited, buy the company report.

GST

Aspiro Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AAMCA4474H1ZFTelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Aspiro Pharma Limited, buy the company report.

Recent activity

Aspiro Pharma Limited has 21 board changes on record since 2014: 6 appointments and 15 cessations. The latest: Bhaskarreddy Pabbatireddy was appointed as Additional Director on 10 Oct 2025.

Appointed
Bhaskarreddy Pabbatireddy was appointed as Additional Director.
AGM
Aspiro Pharma Limited last Annual general meeting of members was held on 24 Jul 2025 as per latest MCA records.
Filing
Aspiro Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge registered on 29 Apr 2015 via Charge ID 10569865 with State Bank Of Mysore was fully satisfied on 18 Nov 2024.
Charges
A charge with Others amounted to Rs. 100.00 Cr with Charge ID 100989753 was registered on 30 Sep 2024.
Ceased
Reddy Narsimha ceased to be Additional Director.
Appointed
Reddy Narsimha was appointed as Director.
Charges
A charge with Others amounted to Rs. 0.09 Cr with Charge ID 100928366 was registered on 10 May 2024.
Charges
A charge with Others amounted to Rs. 105.00 Cr with Charge ID 100907989 was registered on 03 Apr 2024.
Charges
A charge with Others amounted to Rs. 0.13 Cr with Charge ID 100824319 was registered on 04 Nov 2023.
Charges
A charge with Others amounted to Rs. 0.10 Cr with Charge ID 100809427 was registered on 26 Oct 2023.
Ceased
Mahesh Ramappa Kamalamma Hassan ceased to be Additional Director.

29 earlier events are in the company report.

Frequently asked questions

Aspiro Pharma is an active public limited company based in Markook, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 February 2014 (12+ years old) and is registered under CIN U24100TG2014PLC092771.

Aspiro Pharma has 6 current directors:

The latest financial statements of Aspiro Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 24 July 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Aspiro Pharma is 36AAMCA4474H1ZF, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Aspiro Pharma is U24100TG2014PLC092771. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Aspiro Pharma has 9 court cases on record: 2 filed by the company and 7 filed against it. Most are in the district courts.

Aspiro Pharma was incorporated on 05 February 2014, making it 12+ years old. It is registered with the Registrar of Companies, Hyderabad.

Aspiro Pharma has 8 deals on record (5 funding rounds, 3 secondary share transfers), with disclosed funding of ₹998.75 Cr; the latest was in October 2025.

The peers of Aspiro Pharma by revenue are Milan Laboratories (India) Private Limited, Recipharm Pharmaservices Private Limited, Albert David Ltd, Themis Medicare Limited, all in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Bhaskarreddy Pabbatireddy was appointed as Additional Director on 10 Oct 2025. Reddy Narsimha ceased to be Additional Director on 18 Aug 2024. Reddy Narsimha was appointed as Director on 03 Aug 2024. Aspiro Pharma has 21 board changes on record in total.

Aspiro Pharma has 12 MSME Form 1 returns on record between 2016 and 2024, listing 198 overdue payments to 48 micro and small suppliers. The latest return was filed on 25 Apr 2024.

Aspiro Pharma can be reached through the website aspiropharma.com. Its registered office is in Markook, Telangana, India.